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ABSTRACT 
Hepatitis B virus (HBV) is one of the most well recognised human carcinogens. Since its discovery about 40 years 
ago, HBV has been studied extensively. This article summarises the evidence derived from various studies including 
epidemiological, animal model, histopathology studies and molecular genetics studies leading to the establishment of 
HBV as the main aetiological agent for hepatocellular carcinoma (HCC). The reduction in the incidence of childhood 
HCC due to mass hepatitis B vaccination in Taiwan is a dramatic demonstration of the critical aetiological role of 
hepatitis B in HCC. Thus it is essential for interventionalists to understand the epidemiological and pathogenesis of HCC 
to ensure optimal patient care. © 2006 Biomedical Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
Hepatocellular Carcinoma (HCC) is one of the most 
common cancers affecting Asians. In the overwhelming 
majority of cases, it is associated with chronic hepatitis B 
infection [1,2], which appears to be the cause of 50% to 
60% of HCC worldwide [3]. Other recognised causes of 
HCC  are  chronic  hepatitis  C  infection,  alcoholic  liver 
disease and other chronic liver diseases, which can lead 
to liver cirrhosis. HCC is a late complication of chronic 
hepatitis B infection that usually occurs at the fourth and 
fifth decade of life especially when the patients are older 
or liver cirrhosis has developed. The aim of this review is 
to  provide  the  available  evidence  demonstrating  the 
causal  link  between  chronic  hepatitis  B  infection  and 
HCC. 
EPIDEMIOLOGICAL OBSERVATIONS 
Ecological Comparison Studies 
The earliest epidemiological studies have shown that 
areas with a high prevalence of hepatitis B infection were 
also areas with the highest incidence of HCC (Table 1) 
[4,5]. For example, countries in the East Asian region - 
China, Taiwan, Korea and Japan where the prevalence 
rate of hepatitis B infection is very high, were also areas 
with the highest incidence of HCC. The burden of HCC 
in this region in fact, constitutes about 66% of the total 
number of HCC cases worldwide [6]. The risk factor for 
the  high  incidence  of  HCC  in  this  area  is  hepatitis  B 
infection  where  the  attributable  risk  from  this  viral 
infection ranged from 40% to 90% [7]. 
Another  interesting  observation  which  is  closely 
related to the above observations is the preponderance of 
HCC  amongst  certain  ethnic  groups  with  a  high 
prevalence of hepatitis B infection. This observation is 
well seen in the multiethnic countries of Southeast Asia 
of  Malaysia  and  Singapore  where  three  major  Asian 
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races have co-existed for more than two generations. In 
these countries, the Chinese have the highest incidence 
of  HCC  and  the  highest  prevalence  of  hepatitis  B 
infection  compared  with  the  Malays  and  Indians  who 
have a much lower prevalence of hepatitis B infection [8]. 
Longitudinal Cohort Follow-up Studies 
Longitudinal cohort follow-up studies have provided 
the  most  persuasive  evidence  supporting  the  causal 
association between HBV infection and HCC. Beasley et 
al conducted one of the largest epidemiological studies 
so far, involving 22,707 Chinese male civil servants in 
Taiwan [9]. Three thousand four hundred and fifty four 
patients or 15.2% of the study population were HBsAg-
positive.  The  initial  results  from  this  extensive  study 
were  published  in  1981  after  a  mean  duration  of  3.3 
years follow-up constituting 75,000 man-years follow-up. 
During this period of follow-up, there were 307 deaths, 
41 due to primary HCC and 19 due to liver cirrhosis, 
which accounted for 19.5% of the total deaths. Of the 41 
patients who died of HCC, 40 were HBsAg-positive and 
only one was HBsAg-negative. This gave rise to a highly 
significant calculated relative risk of 223 among patients 
who were HBsAg-positive and dying of primary HCC. 
Among the 19 patients who died of liver cirrhosis, 17 of 
them were HBsAg-positive. The HBsAg-positive status 
was  therefore  significantly  associated  with  a  marked 
increase in the incidence of death due to HCC and liver 
cirrhosis. 
A  further  follow-up  review  in  1986  with 
approximately  202,000  man-years  of  follow-up  at  an 
average of 8.9 years per man showed a further 161 cases 
of HCC. One hundred and fifty two cases were HBsAg-
positive, giving rise to an incidence of HCC of 494.5 per 
100,000  population  per  year  among  HBsAg  carriers 
 
Figure 1  Comparison of the Incidence of Liver Cancer in Children 6 to 14 and 0 to 5 Years of Age, 
According to Birth Cohort [11] (reproduced with kind permission). 
Table 1  Prevalence of hepatitis B and incidence of liver cancer. 
Liver cancer incidence 
ASR (per 100,000 population) [5] 
Country  Prevalence of HBV (%)* 
[4] 
Male  Female 
China  5.3-12  37.9  14.2 
South Korea  2.6-5.1  47.1  11.4 
Thailand  4.6-8  38.6  17.2 
USA  0.2-0.5  5.5  2.0 
UK  < 1  3.3  1.7 
Germany  0.62  4.2  1.5 
Canada  0.5-1.0  4.0  1.4 
 
ASR – Age Standardised Rate 
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compared with 5.3 among the non-HBsAg carriers. The 
relative risk of HCC among HBsAg-carriers compared to 
non-HBsAg carriers for this data was 98.4 (95% CI=50.2 
to 193) [10]. 
This  Taiwan  prospective  study  provided  the 
strongest evidence of the role of chronic HBV infection 
as an aetiological agent in the causation of HCC. 
Effect of mass vaccination on liver cancer incidence 
rates in children 
With the identification of HBV infections as a major 
aetiological  factor  in  HCC,  a  nationwide  hepatitis  B 
vaccination  program  was  implemented  in  Taiwan,  the 
first such program worldwide in1984. Within 10 years, 
this program had successfully reduced the HBV carrier 
rate in children from 10% to 1%. The implementation of 
such  a  comprehensive  vaccination  program  in  Taiwan 
has  allowed  important  epidemiological  observations  to 
be made with respect to the incidence of HCC. 
In  Taiwan,  the  association  of  HBV  and  HCC  is 
stronger  in  children  than  in  adults.  The  rate  of 
seropositivity  for  HBV  nearly  approached  100%  in 
children with HCC as compared to 70% to 80% in adults. 
Although,  the  incidence  of  childhood  HCC  is  low 
worldwide, the incidence of HCC in Taiwan is relatively 
high  and  therefore,  any  changes  in  the  incidence  rate 
would be easier to detect and measure.  
In  1994,  Chang  et  al  [11]  studied  the  impact  of 
universal  hepatitis  B  vaccination  in  Taiwan  on  the 
incidence of HCC in children. In general, the incidence 
of HCC in children aged six to 14 years old showed a 
declining trend from 1981 to 1994. It was reported that 
the average annual incidence of HCC in these children 
between 1981 and 1986 was 0.70 per 100,000 children 
(range, 0.65 to 0.78). The incidence declined to 0.57 per 
100,000 children (range, 0.48 to 0.62) between 1986 and 
1990.  This  rate  further  dropped  to  0.36  per  100,000 
children (range, 0.23 to 0.48) between 1990 and 1994. 
This reduction in the annual incidence rate was highly 
significant statistically (p<0.01). The reduction in cancer 
incidence  was  seen  with  HCC  only,  while  the  annual 
incidence of other childhood cancers during this period 
remained  similar  indicating  that  the  change  in  HCC 
incidence must be specifically related to the change in 
the  prevalence  of  hepatitis  B  infection  rather  than  a 
general change in the environment or living conditions. 
In addition, the reduction in the incidence of liver cancer 
was  seen  only  in  children  aged  six  to  14  years  old 
whereas the incidence remained unchanged in children 
aged up to five years old, in whom the aetiology of liver 
cancer was due to hepatoblastoma rather than hepatitis B 
infection (Figure 1).  
ANIMAL MODELS 
The  wood  chuck  hepatitis  virus  has  similar 
characteristics  with  the  human  hepatitis  B  virus  and 
provides  an  excellent  animal  model  to  study  the 
pathogenesis of HCC. In the wild, animals infected with 
the  woodchuck  virus  (WHV)  have  been  shown  to 
develop  liver  cancer.  In  experimental  conditions, 
inoculation  of  a  high  dose  of  WHV  results  in  the 
development  of  HCC  in  almost  100%  of  the  animals. 
Laboratory studies have shown integration of the WHV 
DNA  with  the  woodchuck  hepatocyte  DNA.  The 
woodchuck model demonstrates to us that liver cancer 
can develop following a viral infection of the liver. [12, 
13] 
HISTOPATHOLOGY STUDIES IN HUMANS 
Scientists  had  postulated  the  association  between 
HBV and HCC based on ecological comparison studies 
but were initially unable to demonstrate the virus within 
the HCC tissue until 1970s when a Japanese pathologist, 
Shikata,  developed  a  histochemical  stain  called  orcein 
stain [14], which could stain the HBsAg within the tissue 
and  thereby  allowing  the  identification  of  the  virus  in 
liver  tissue.  Subsequently,  more  sophisticated  staining 
methods  were  developed  such  as  immunoperoxidase 
technique and indirect immunofluorescence. These new 
techniques allowed scientists to study the association of 
HBV and HCC in greater depth. Many such studies have 
been published since then. One study done in Singapore 
[15] showed orcein-positive liver cells in 37 out of 50 
(74.0%) cases of HCC, and only five out of 113 (4.4%) 
in  the  control  group.  In  addition,  there  was  also  a 
significant difference in the frequency of HCC in orcein-
positive and orcein-negative cirrhotic livers (28 out of 50 
and  10  out  of  40  respectively).  Akagi et  al  [16]  from 
Japan analysed 105 autopsy cases of HCC and found that 
HBsAg was detected with the orcein stain in 58 cases 
(55.2%) compared with four out of 171 cases (2.3%) of 
control  group.  These  results  demonstrated  a  close 
association between HBV and HCC. 
MOLECULAR STUDIES 
Further evidence derived by using molecular studies 
has  strengthened  the  causal  relationship  of  HBV  and 
HCC. It has been demonstrated that the incorporation of 
certain  viral  particle  such  as  HBV  DNA  into  the  host 
genome can act as a precursor to HCC. The viral double 
stranded DNA encodes four types of genes i.e. surface 
gene for HBsAg, core gene for HBcAg, polymerase gene 
for HBV DNA and X gene for HBxAg. HBsAg, HBcAg, 
HBV DNA and HBxAg all have been found within HCC 
tumour in the tissue specimen. HBV DNA occurs mainly 
in  two  forms  of  infected  hepatocytes,  the  covalently 
closed circular (ccc) DNA and the integrated DNA. The 
cccDNA  serves  as  the  template  for  host  RNA 
polymerase II, which initiates the production of HBsAg, 
HBcAg,  viral  DNA  polymerase  and  HBxAg.  Whereas 
the integrated DNA predominates in HCC cell nuclei and 
has been shown in several studies to contain enhancers 
that  may  modulate  several  liver  specific  genes, 
transcriptional  activators  and  alteration  of  the  X  gene 
functions.  Although  the  actual  mechanisms  of CH Wong et al. Biomed Imaging Interv J 2006; 2(3):e7    4 
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hepatocarcinogenesis remain unclear, HBxAg have been 
implicated as the most important viral product that cause 
direct malignant cell transformation in the pathogenesis 
of HCC. Several in vitro studies have shown the effects 
of  HBxAg  on  cellular  repair,  proto-oncogenes,  tumour 
suppressor  gene,  anti-apoptotic  pathway  and  the 
induction  of  HCC  in  transgenic  mice.  These  evidence 
support the probable direct effect of a HBV component, 
HBxAg, in the development of HCC [17-24]. 
EPILOGUE 
The  causal  link  between  chronic  hepatitis  B 
infection and HCC is irrefutable. With mass vaccination 
at birth in place in most countries in Asia, and improved 
socio-economic conditions, the prevalence of hepatitis B 
infection  will  steadily  decline.  In  countries  where  this 
has happened such as in Japan, hepatitis B is now the 
main  “cause”  of  HCC  as  in  the  West.  At  present, 
however,  hepatitis  B  remains  prevalent  in  Asia  and 
prevention will continue to result in marked decrease in 
the incidence of HCC. 
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